Ascendis Pharma

ASND · NASDAQ · USD

227,31 $Variazione rispetto alla chiusura precedente: −0,23%Variazione assoluta: −0,52 $

Chiusura · 1 ottobre 2026

Profilo dell'azienda

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Descrizione disponibile in inglese.

Dati societari

Settore
Salute
Industria
Biotechnology
Sede
Tuborg Boulevard 12, 2900, Hellerup
Dipendenti
1.189
Quotazione
ASND · NASDAQ
Valuta
USD